Overview

Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections

Status:
RECRUITING
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of interferon α1b (GB05) in the treatment of children under 2 years of age with respiratory syncytial virus infection.
Phase:
PHASE3
Details
Lead Sponsor:
Kexing Biopharm Co., Ltd.